These cancers depend on rogue cells multiplying uncontrollably caused by DNA abnormalities (mutations) in important pathways involved in the generation of cancer and cancer stem cells. When there are mutations in these pathways, cancer cells and cancer stem cells, run rogue, multiply and spread uncontrollably.
Take a biopsy (current procedure).
Analyse tumour tissue for critical mutations. This is a simple test using established technology.
Select patients whose tumours have critical mutations.
Treat selected patients with the matching pathway inhibitor. Anastasis has several pathways inhibitors ready for development.
This treatment, by targeting specific and critical mutations, could potentially provide a breakthrough in the treatment of cancer types with significant clinical unmet need.
Anastasis has raised funding through Crowdcube, in excess of £150,000, which was its initial objective, allowing the Company to accelerate its R+D program and also support research into stability and cellular activity of its drug compounds at the University of Chicago, USA.
Editorial : Basic Research in Cardiology 2020, 115:31
Paola Rizzo University of Ferrara, Italy
Abstract 17601, A clinical trial without patients, UK and Cyprus
This is an innovative molecular imaging ‘phase I/II’ trial assessing biodistribution, PK, PD, mode of action , toxicity and efficacy of a novel Mastermind inhibitor prior to entering the clinic.